Teratology Information Service, Helsinki University Central Hospital and HUSLAB, Helsinki, Finland.
Reprod Toxicol. 2010 Sep;30(2):249-60. doi: 10.1016/j.reprotox.2010.04.015. Epub 2010 May 4.
Prenatal exposure to selective serotonin reuptake inhibitors (SSRIs) may increase risk for congenital malformations and adverse perinatal outcome.
This article reviews the published literature on exposure to SSRIs in utero and during lactation.
Literature search in PubMed.
There is no conclusive evidence for increased risk for malformations but paroxetine and possibly fluoxetine use in early pregnancy may be associated with a small increased risk for cardiovascular malformations. Perinatal adverse effects, including respiratory distress and neonatal adaptation problems are common in exposed infants, and an increased risk for persistent pulmonary hypertension of the newborn (PPHN) has been observed. The suspected increased risk of preterm birth, low birth weight or small for gestational age has not been confirmed. It is not clear to what extent the adverse effects observed in some studies are attributable to the drug effect or related to mother's underlying disease and other possible confounders. The SSRIs are usually compatible with breastfeeding, however, individual variations in infant exposure may occur.
产前暴露于选择性 5-羟色胺再摄取抑制剂（SSRIs）可能会增加先天畸形和围产期不良结局的风险。
本文综述了有关 SSRI 宫内和哺乳期暴露的已发表文献。
在 PubMed 中进行文献检索。
没有确凿证据表明畸形风险增加，但帕罗西汀和可能的氟西汀在妊娠早期使用与心血管畸形的小风险增加有关。围产期不良影响，包括呼吸窘迫和新生儿适应问题在暴露婴儿中很常见，并且观察到新生儿持续性肺动脉高压（PPHN）的风险增加。早产、低出生体重或小于胎龄儿的风险增加尚未得到证实。尚不清楚一些研究中观察到的不良影响在多大程度上归因于药物作用，或与母亲的基础疾病和其他可能的混杂因素有关。SSRIs 通常与母乳喂养兼容，但婴儿暴露的个体差异可能会发生。
